Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co.,...
MAXVAX Biotech Raises RMB500M in Series B to Advance Vaccine Pipelines
MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9...
Livzon’s V-01 and V-01D-351 Vaccines Show Strong Safety, Immunity as COVID Boosters
China-based Livzon Pharmaceutical Group (HKG: 1513) released clinical data for its recombinant novel coronavirus fusion...
CANbridge Pharmaceuticals Doses First Patient in CAN103 Gaucher Disease Trial
China-based rare disease firm CANbridge Pharmaceuticals announced the dosing of the first patient in a...
InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to Advance FAK Inhibitor IN10018
China-based biotech firm InxMed (Nanjing) Co., Ltd announced it has received $10 million in debt...
Frontera Therapeutics Raises $160M in Series B to Advance Gene Therapy FT-001
Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round,...
DAC Biotech’s DXC005 ADC Doses First Patient in Beijing Cancer Hospital Trial
China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its...
J&J Q2 Sales Rise 8% but Profits Plunge 23% Amid China COVID Lockdowns
US giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q2 2022 financials, showing 8.0% year-on-year...
Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx
Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant...
Aidea Pharmaceutical Acquires 19.96% ND Pharm Stake to Boost Urokinase Business
China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has acquired a 19.96% stake in ND...
NHSA Issues New Medical Service Pricing Policy to Enhance Public Welfare and Innovation
The National Healthcare Security Administration (NHSA) has released a new notification on medical service pricing...
MicroPort CardioFlow Completes First Clinical Use of Dry Valve Transcatheter Mitral Valve System
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
WuXi Biologics to Build $1.4B CRDMO Hub in Singapore, Creating 1,500 Jobs
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
Antengene and Celularity Partner on Bispecific Antibody and NK Cell Therapy Combo
China-based Antengene Corporation Ltd (HKG: 6996) announced a preclinical partnership with U.S. firm Celularity Inc....
Kexing Pharmaceutical Launches Phase III Influenza Vaccine Study in Chile
China-based Kexing Pharmaceutical (SHA: 688136) announced the start of a Phase III clinical trial in...
Henlius Biotech’s HLX14 Biosimilar Wins TGA Approval for Global Phase III Osteoporosis Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) received approval from Australia’s Therapeutic Goods Administration (TGA)...
Luye Pharma’s Rotigotine Microspheres Meet Phase III Goals in Parkinson’s Study
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for rotigotine...
Eli Lilly’s Retevmo Wins Special Approval in China’s Lecheng Medical Pilot Zone
Eli Lilly & Co. (NYSE: LLY) has secured special approval for its RET kinase inhibitor...
Attec Completes Pre-Series A Financing with Sequoia China Backing Protein Degradation Tech
China-based biotech startup Attec has completed a pre-Series A financing round, with its protein degradation...
Innovent Biologics’ Mazdutide Meets Phase II Goals in Type 2 Diabetes Study
China-based Innovent Biologics Inc. (HKG: 1801) announced that its Phase II study of mazdutide (IBI362/OXM3)...